Integra LifeSciences Holdings Corporation (IART) is a Medical - Devices company in the Healthcare sector, currently trading at $11.06. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
Analyst consensus target is IART = $15 (+35.6% upside).
Valuation: IART trades at a trailing Price-to-Earnings (P/E) of -1.4 (S&P 500 average ~25).
Financials: revenue is $1.6B, +1.7%/yr average growth. Net income is $516M (loss), growing at -2503.5%/yr. Net profit margin is -31.6% (negative). Gross margin is 51.7% (-10.6 pp trend).
Balance sheet: total debt is $2.0B against $1.0B equity (Debt-to-Equity (D/E) ratio 1.95, leveraged). Current ratio is 2.54 (strong liquidity). Debt-to-assets is 56.4%. Total assets: $3.6B.
Analyst outlook: 12 / 26 analysts rate IART as buy (46%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 94/100 (Pass), Growth 30/100 (Fail), Past 50/100 (Partial), Health 33/100 (Fail), Moat 53/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).
